文献速递艾滋病与性传播感染

多拉韦林在接受血液透析的艾滋病合并终末期肾病患者中的清除情况

Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

一项探索性临床试验纳入8例接受间歇性血液透析的艾滋病病毒感染者,在稳定联合抗逆转录病毒治疗基础上加用多拉韦林100 mg每日一次共5天,第6天透析前后采血并采集透析器出入口及透析液样本。多拉韦林透析提取率为34.3%(25.8%-41.4%),透析前后血浆浓度比值为0.8(0.6-1.0),透析结束时血浆浓度为785(101-1851)ng/mL,仍高于蛋白结合校正的EC50(5 ng/mL),作者认为接受间歇性血液透析者无需调整多拉韦林剂量。

要点

  • 多拉韦林透析提取率为34.3%(25.8%-41.4%),属中等程度清除。
  • 透析前后血浆多拉韦林浓度比值为0.8(0.6-1.0)。
  • 透析结束时血浆浓度785(101-1851)ng/mL,高于蛋白结合校正的EC50(5 ng/mL)。

核心结论

  • 尽管血液透析对多拉韦林有中等程度清除,透析结束后血浆多拉韦林谷浓度仍高于蛋白结合校正的EC50(5 ng/mL),接受间歇性血液透析的艾滋病病毒感染者无需调整多拉韦林剂量。

研究设计与样本

  • 探索性临床试验,纳入接受间歇性血液透析的艾滋病病毒感染者;入组后(第1天)在稳定联合抗逆转录病毒治疗基础上加用多拉韦林100 mg每日一次共5天,第6天透析前后采血并采集透析器入口、出口及透析液样本,用LC-MS/MS测定多拉韦林浓度,计算透析前后血浆浓度比值和透析提取系数;研究注册号NCT04689737。

主要发现

  • 共纳入8例参与者(6例男性),中位(范围)年龄49.5(28-67)岁,BMI为23.6(17.9-34.2)kg/m2。
  • 多拉韦林透析提取率为34.3%(25.8%-41.4%)。
  • 透析前后血浆多拉韦林浓度比值为0.8(0.6-1.0)。
  • 透析结束时(给药后20.8-27.3 h)血浆多拉韦林浓度为785(101-1851)ng/mL。

关键数值与推荐

  • 多拉韦林透析提取率34.3%(25.8%-41.4%)。
  • 透析前后血浆多拉韦林浓度比值0.8(0.6-1.0)。
  • 透析结束时血浆多拉韦林浓度785(101-1851)ng/mL,高于蛋白结合校正的EC50(5 ng/mL)。

临床怎么用

  • 作者认为,接受间歇性血液透析的艾滋病病毒感染者无需调整多拉韦林剂量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the effect of haemodialysis on doravirine concentrations in people living with HIV (PLWH) undergoing routine haemodialysis. METHODS: An exploratory clinical trial that included PLWH undergoing intermittent haemodialysis was undertaken. After enrolment (day 1), doravirine 100 mg once daily was added to stable combined ART for 5 days. On day 6, blood samples were collected from each participant at the beginning and at the end of a dialysis session. Additionally, paired samples of blood entering ('in') and leaving ('out') the dialyser and the resulting dialysate were collected during the dialysis session to evaluate drug removal during dialysis. Doravirine concentrations in plasma and in the dialysate were determined by LC-MS/MS. The ratio of doravirine concentrations in plasma after/before the haemodialysis session and the haemodialysis extraction coefficient were calculated for each participant. The study was registered at https://www.clinicaltrials.gov (NCT04689737). RESULTS: Eight participants (six male) were included. The median (range) age and BMI were 49.5 (28-67) years and 23.6 (17.9-34.2) kg/m2, respectively. The doravirine dialysis extraction ratio was 34.3% (25.8%-41.4%). The ratio of doravirine concentrations in plasma after/before the haemodialysis session was 0.8 (0.6-1.0). At the end of the haemodialysis session (time post-dose 20.8-27.3 h), doravirine concentrations in plasma were 785 (101-1851) ng/mL. CONCLUSIONS: Despite moderate removal of doravirine by haemodialysis, trough doravirine concentrations in plasma after the haemodialysis sessions remained in excess of the protein-binding-adjusted EC50 (5 ng/mL). Doravirine dosage adjustments are unnecessary in PLWH undergoing intermittent haemodialysis.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Moltó J, Graterol F, Curran A, et al. Removal of doravirine by haemodialysis in people living with HIV with end-stage renal disease. J Antimicrob Chemother. 2022. PMID: 35425985. doi:10.1093/jac/dkac126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。